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In vitro assays play an important role in the discovery and development of new antileishmanial drugs. The
classic macrophage-amastigote models using murine peritoneal macrophages or human-monocyte
derived macrophages as host cells are useful for drug screening. A major limitation of these models is
the dependence on microscopic counting, a time-consuming and subjective method of analysis. The pres-
ent study describes a detailed protocol for applying quantitative real-time PCR (qPCR) as an accurate and
sensitive tool to assess parasite load in an amastigote-macrophage model. This assay can be performed in
a standardized medium-to-high throughput procedure, replacing traditional readout of number of amas-
tigote per macrophages by DNA load measurement.
 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Leishmaniasis is one of the world’s most neglected diseases.
About 12 million people are currently infected, and an estimated
2 million new cases (1.5 million cases of cutaneous leishmaniasis
and 500,000 cases of visceral leishmaniasis) occur annually (World
Health Organization, 2011). Chemotherapy and vector control are
available tools in combating this disease, as effective vaccines are
still under development (Chawla and Madhubala, 2010).
Pentavalent antimonials have been used in the treatment of
leishmaniasis for more than 60 years, despite their disadvantages
that includes parenteral administration, long-term therapy, and
potentially severe side effects associated with dosage and toxicity.
In addition, acquired resistance to pentavalent antimonials has
been developed in the high-prevalence, high-transmission epi-
demic areas of India (Seifert, 2011).
Amphotericin B is currently used as ﬁrst line drug in areas with
high rates of unresponsiveness to antimonials and as second line
treatment elsewhere. Miltefosine and paromomycin have recently
been used, but all these options suffer from limitations such as
cost, speciﬁc toxicities and parenteral administration (Croft et al.,
2006; de Oliveira-Silva et al., 2008; Dujardin et al., 2010; Seifert,
2011). Thus, the development of new antileishmanial chemother-
apy is urgently needed to efﬁciently combat and eliminate this
disease.sevier OA license. In vitro assays play an important role in primary screening for
new antileishmanial drugs. Macrophage-amastigote model using
murine peritoneal macrophages or human monocyte-derived mac-
rophages is the most widely used assay for testing drugs against
Leishmania species (Gupta and Nishi, 2011). This model yield
essential information on drug activity in the parasite’s natural
environment and identify species/strain variations in drug sensi-
tivity. The activity of the test drug is usually measured by micro-
scopic counting of the percentage of infected cells or the number
of amastigote per cell through of 50–300 macrophages examina-
tion. This is a time-consuming and subjective method of analysis,
not adaptable to medium-to-high throughput screening models
(Fumarola et al., 2004; Croft et al., 2006; Sereno et al., 2007; Gupta
and Nishi, 2011).
In this study, quantitative real-time PCR (qPCR) was validated
as a reliable tool to assess parasite load in amastigote-macrophage
assays. Measuring amphotericin B activity against Leishmania.
(Leishmania) infantum (syn. L (L.) chagasi), qPCR analysis compared
favorably to the classic method of microscopic counting of intracel-
lular amastigotes.2. Material and methods
2.1. Antibiotics
Amphotericin B (Anforicin B; Cristália, Brazil) was obtained as a
sterile powder. The powder was reconstituted with sterile water
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ium (Sigma–Aldrich, St. Louis, USA) for amastigote-macrophage
cultures immediately before assays were performed.
2.2. Parasites and cultivation of amastigote-like forms
L. infantum strain MHOM/BR/70/BH46 was used in this study.
Amastigote-like forms were transformed from stationary-phase
promastigotes, cultivated in Schneider’s insect medium (Sigma–Al-
drich) supplemented with 10% heat-inactivated fetal bovine serum
(FBS; GIBCO, Grand Island, NY, USA) at pH 7.2, 26 C. Promastigotes
were centrifuged (10 min/1000 g), resuspended in Schneider’s
medium, and transformed according to the species-speciﬁc proto-
col for L. infantum at 32 C, pH 7.2 in 20% FBS for 6 days.
2.3. Amastigote-macrophage assay for L. infantum
Balb/c mice were injected intraperitoneally with 1.5 mL of 3%
thioglycolate medium (Biobrás, Montes Claros, Brazil). After 96 h,
peritoneal macrophages were harvested by peritoneal lavage using
cold RPMI-1640 medium (Sigma–Aldrich). Cells were counted,
centrifuged, and resuspended at a concentration of 4  105/mL in
RPMI medium without supplements. Sterile round glass coverslips
(13 mm) were placed in each well of 24-well culture plates. Five
hundred microliters of the macrophage suspension was added to
each well, and the macrophages were allowed to attach to the cov-
erslips for 2 h at 37 C in 5% CO2. After 2 h, the medium was re-
moved from the wells and replaced with 500 lL of warm (37 C)
RPMI containing 10% FBS plus penicillin (50 U/mL) and streptomy-
cin (50 lg/mL). A suspension of 3.6  106/mL amastigote-like L.
infantum was added to each well in 500 lL of RPMI (macro-
phage:parasite ratio of 1:9), after 18–24 h. The plates were incu-
bated for 4 h at 37 C in 5% CO2, and the medium was aspirated
to remove free-ﬂoating parasites. Fresh RPMI (1 mL) containing
amphotericin B or not at the appropriate concentrations (0.3,
0.12, 0.048, 0.0196 and 0.0078 lg/mL) was added to the wells in
triplicate. The plates were incubated for 72 h at 37 C in 5% CO2.
Three independent experiments were performed in triplicate
for each drug concentration to determine amphotericin B activity
in the amastigote-macrophage model using microscopic counting.
Two of these independent experiments were also assessed by
qPCR.
Animals were handled according to local and federal regula-
tions, and the research protocols were approved by the Fiocruz
Committee on Animal Research (protocol P-0321/06; license
L-0024/8).
2.4. Drug activity measured by microscopic counting of the
amastigote-macrophage assay
The medium was aspirated, and the coverslips were removed,
methanol ﬁxed, air-dried, and glued to microscope slides. After
staining with Giemsa, 100 cells were counted along the border of
the coverslips under optical microscope with a 100x oil-immersion
objective. The results were expressed as the number of amastig-
otes-100 macrophages in treated and untreated cultures.
2.5. Drug activity measured by qPCR analysis of the amastigote-
macrophage assay
The medium was aspirated, and the coverslips were removed. A
simple protocol using Trypsin/EDTA was developed to detach the
macrophages from the coverslips. In new 24-well culture plates,
150 lL of 0.25% trypsin/EDTA (Invitrogen, Camarillo, CA, USA)
was applied to the coverslips and removed immediately. The plates
containing the treated coverslips were incubated for 5 min at 37 Cin 5% CO2. Each coverslip was washed ﬁve times with 400 lL of
sterile PBS (phosphate buffered saline), and the entire volume
(1200 lL) was collected in a Falcon tube. The coverslips were
placed in the tubes, which were then centrifuged at 300 g for
7 min. Only 400 lL of the supernatant was left for the cell pellets,
and cell concentrations were determined using a Neubauer cham-
ber. The tubes were stored at 70 C until the DNA extraction.
Total DNA was extracted using the QIAampDNA Mini kit (Qia-
gen, GmbH, Hilden, Germany) following the protocol for cultured
cells, increasing the volumes of Buffer AL, proteinase K and ethanol
(96–100%) accordingly for a 400 lL sample volume. Additionally,
5 lg of poly dA carrier DNA (Sigma–Aldrich) was added to each
sample. The ﬁnal elution volume was 60 lL. The concentration
and purity of the extracted DNA were determined spectrophoto-
metrically by reading A260 and A280 on a NanoDrop ND-1000 (Ther-
mo Fisher Scientiﬁc, Wilmington, DE, USA).
Two independent assays for the detection and quantiﬁcation of
Leishmania and mouse DNA were developed using the Applied Bio-
systems StepOnePlusTM Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA).
For the Leishmania assay, the target DNA was the small-subunit
ribosomal RNA (SSU rRNA) gene, which is conserved among all
Leishmania species. About 160 copies of the SSU rRNA gene are
present in every Leishmania cell (van Eys et al., 1992). The Leish-
mania assay consisted of the primers LEIS.U1 (50-AAGTGC
TTTCCCATCGCAACT-30) and LEIS.L1 (50-GACGCACTAAACCC
CCTCCAA-30), designed to amplify a 67-bp fragment and the ﬂuoro-
genic probe LEIS.P1 (FAM 50-CGGTTCGGTGTGTGGCGCC-30 TAMRA).
These primers were chosen to confer sensitivity and speciﬁcity sat-
isfactory to the test (Wortmann et al., 2001). Each sample ampliﬁ-
cation was performed in triplicate in a ﬁnal volume of 20 lL,
including 3 lL of template DNA, 10 lL of TaqMan Universal PCR
Master Mix 2 (Applied Biosystems), 0.3 lM of each primer and
0.25 lM of the probe. The optimized PCR ampliﬁcation conditions
were 50 C for 2 min (UNG activation), 95 C for 10 min and 40 cy-
cles of 95 C for 15 s and 60 C for 1 min. The threshold of detection
and the baseline were automatically determined using StepOne™
Software v2.1. A blank consisting of the reaction mixture and water
instead of DNA template was included in each qPCR run.
For the mouse assay, the ACTB reference gene was used as tar-
get (Giulietti et al., 2001). The primers 50-AGAGGGAAATCGTGCGT-
GAC-30 (forward) and 50-CAATAGTGATGACCTGGCCGT-30 (reverse)
were designed to amplify a 138-bp fragment. Reaction mixtures
contained 12.5 lL of Syber Green PCR Master Mix 2X (Applied
Biosystems), 0.1 lM of each primer, and 3 lL of DNA template in
a ﬁnal volume of 25 lL. Thermal cycling comprised an initial dena-
turation step at 95 C for 10 min, followed by 40 cycles of 95 C for
15 s and 60 C for 1 min. To conﬁrm speciﬁcity of the mouse assay,
a ﬁnal melting curve analysis was conducted with incubation at
95 C for 15 s, 60 C for 1 min, followed by a continuous tempera-
ture increase from 60 to 95 C at a rate of 0.3 C/s. The melting tem-
perature of the amplicons was automatically determined by
software analysis. Each sample ampliﬁcation was performed in
triplicate, and a blank consisting of the reaction mixture and water
instead of DNA template was included in each qPCR run.
Standard curves were prepared for each assay using known
quantities of pCR 4 TOPO vector (Invitrogen, São Paulo, Brazil)
containing the cloned mouse gene (ACTB; 138 bp) and the 67 bp
L. infantum SSU rRNA fragment. The recombinant plasmids were
serially diluted 1:10 to create each standard curve. For the Leish-
mania assay, 160 copies of the SSU rRNA gene represented a single
parasite cell. The quality parameters of the standard curves, includ-
ing PCR efﬁciency, linear dynamic range and correlation coefﬁcient,
were obtained by software analysis.
Parasite load was quantiﬁed by two distinct methods. In the
ﬁrst method, the total DNA concentration of each sample was
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malization factor (F). Parasite density (PD) was calculated using the
equation proposed by Rolão et al. (2004):
PD = [(N  P)/F]  [100 macrophages/number of macrophages,
as quantiﬁed using a Neubauer chamber]. PD refers to parasite
density (number of amastigotes-100 macrophages), N is the num-
ber of parasites obtained and P is the proportion between the
amount of DNA used in the technique (3 lL) and the total volume
of the eluted DNA (60 lL). In the second method, the parasite load
was expressed by the Leishmania DNA load (relative copy number
of the 67 bp SSU rRNA fragment) normalized against the reference
gene ACTB, according to Overbergh et al. (1999). ACTB copy num-
bers for the target samples were divided by the highest ACTB value
obtained in the experiment, resulting in a correction factor used for
normalization.
Results were expressed as the number of amastigotes-100 mac-
rophages (or the Leishmania DNA load) in treated and untreated
cultures.2.6. Data analysis
Data were processed with GraphPad Prism version 5.00 for
Windows (San Diego, CA, USA). All quantitative variables were
individually assessed with the one-sample Kolmogorov–Smirnov
test for normality. The parasite load measured by microscopic
counting and both methods of qPCR assessment were analyzed
using the Pearson’s parametric correlation coefﬁcient. In order to
determine the variability of the qPCR assay, intra-assay (repeat-
ability) and inter-assay (reproducibility) precision levels were
measured by comparing the means ± the S.D. and reported as coef-
ﬁcients of variation (CVs, S.D./mean  100%). The 50% and 90%
inhibitory concentrations (IC50 and IC90, respectively) of amphoter-
icin B were calculated using sigmoid dose–response curves and the
95% conﬁdence intervals (95% CI) were included. The level of sig-
niﬁcance was set at P < 0.05.3. Results
3.1. qPCR assay performance
In the initial experiments, the performance of the Leishmania as-
say was evaluated by making serial dilutions ranging from
2.54  102 to 2.54  108 copies of the linearized plasmid DNA con-
taining the 67-bp fragment (equivalent to 1.5–1.5  106 Leishmania
cells). The mean standard curve calculated from ﬁve independent
experiments was linear over an at least 6-log10 range of DNA con-
centrations, with a correlation coefﬁcient of 0.99. The PCR efﬁ-
ciency of ampliﬁcation was 99.9%, and the inter-assay
coefﬁcients of variance, calculated from triplicates of the same
10-fold DNA dilutions, ranging from 1.5  106 to 15 parasites and
performed on separated runs were 5.17%, 6.39%, 5.17%, 4.90%,
4.98% and 4.89%, respectively. Intra-assay coefﬁcients of variance,
calculated from triplicates of the same six different concentrations
and performed on the same plate were 0.16%, 0.73%, 0.50%, 0.43%,
1.98% and 2.06%, respectively. Similar results were obtained with
the mouse assay (data not shown).
The Leishmania assay was positive for samples with 2.54  102
copies of linearized plasmid DNA, corresponding to 1.5 Leishmania
cells. The limit of detection was also evaluated by making serial
dilutions of L. infantum genomic DNA in water to obtain the points
of the curve spanning from 12,000 to 0.012 pg/lL. To convert the
amount of DNA detected into parasite numbers, the genome size
of a diploid L. infantum cell (assumed to be 3.2  107 bp – http://
www.sanger.ac.uk) was converted into a mass equivalent, yielding
a value of approximately 0.070 pg. As the assay uses 3 lL of DNAtemplate, 0.036 pg of genomic DNA was detected, representing less
than a single parasite cell.
3.2. Activity of amphotericin B on L. infantum in the amastigote-
macrophage assay
The IC50 and IC90 values for amphotericin B activity against
intracellular L. infantum amastigotes are shown in Table 1. These
values were determined using sigmoid dose–response curves from
three independent microscopic counting experiments and two
independent qPCR experiments using the amastigote-macrophage
model. The activity of amphotericin B was determined at concen-
trations of 0.3, 0.12, 0.048, 0.0196 and 0.0078 lg/mL; an IC50 of
0.02 lg/mL (95% CI: 0.01–0.03) and an IC90 of 0.04 lg/mL (95%
CI: 0.01–0.15) were observed when assessed by microscopic count-
ing. These same results were obtained when assessed by qPCR
regardless of the method of parasite load quantiﬁcation (number
of amastigotes-100 macrophages or Leishmania DNA load).
3.3. Correlation between parasite load estimated by microscopic
counting and qPCR in a L. infantum amastigote-macrophage model
The correlation between the mean parasite load in a L. infantum
amastigote-macrophage model as estimated by microscopic count-
ing and both methods of qPCR assessment are shown in Fig. 1. A
Pearson’s correlation coefﬁcient of 0.987 (P = 0.001) was found
when the parasite load was determined by microscopic counting
or by qPCR, with the results expressed as the number of amastig-
otes-100 macrophages (Fig. 1A). When the correspondence be-
tween microscopic counting and qPCR (expressed as Leishmania
DNA load) was assessed, the observed correlation coefﬁcient was
0.995 (P < 0.001) (Fig. 1B).4. Discussion
Real-time quantitative PCR (qPCR) is considered a very promis-
ing tool for the detection and quantiﬁcation of Leishmania in differ-
ent human clinical samples, with the goal of assessing successful
treatment or premature relapses. This technique has been used
to measure parasite load and evaluate antileishmanial drugs in
the in vivo mouse model (Bretagne et al., 2001; Nicolas et al.,
2002; Garnier et al., 2007; Reimão et al., 2011) and, more recently,
in the in vitro model (Ordóñez-Gutiérrez et al., 2009).
The present study validated the use of qPCR as a sensitive tech-
nique to accurately measure the activity of selected antileishma-
nial drug in an intracellular model. The detailed protocol was
described for the ﬁrst time, enabling medium-to-high throughput
screening into laboratory workﬂow with the possibility of auto-
mated applications in DNA puriﬁcation and PCR setup. This de-
tailed protocol can also be applied to determine parasite load in
therapeutic studies with intracellular models infected with differ-
ent Leishmania species.
The Leishmania qPCR assay performance was strictly measured
to ensure its validity. A mean standard curve derived from ﬁve
independent experiments demonstrated high PCR efﬁciency
(99.9%). This mean standard curve was linear over an at least 6-
log10 range of DNA concentrations (the highest [2.54  108] to
the lowest [2.54  103] quantiﬁable copy number established for
the linearized plasmid DNA with the SSU rRNA 67-bp fragment),
with a correlation coefﬁcient of 0.99. The precision measured by
inter- and intra-assay variability (reproducibility and repeatability,
respectively) was also extremely satisfactory. Evaluation of the
analytical sensitivity of the Leishmania qPCR assay showed that it
could accurately detect 2.54  102 copies of linearized plasmid
DNA, corresponding to 1.5 Leishmania cells. In another approach,
Fig. 1. Correlation between parasite load estimated by microscopic counting and the qPCR assay in an amastigote-macrophage model to assess in vitro amphotericin B
activity against L. infantum. (A) A Pearson’s correlation coefﬁcient of 0.987 (P = 0.001) was found for a comparison considering two independent experiments and the values of
the parasite load determined by microscopic counting and the qPCR assay. The results were expressed by the number of amastigotes-100 macrophages. (B) Considering the
correspondence between microscopic counting and the qPCR assay with the Leishmania DNA load results, a Pearson’s correlation coefﬁcient of 0.995 (P < 0.001) was observed.
The continuous line represents the linear regression.
Table 1
Comparative IC50 and IC90 of amphotericin B against intracellular L. infantum in an amastigote-macrophage assay, as determined by sigmoid dose–response curves.
Methods
Microscopic countinga qPCR assayb amastigotes-100 macrophages qPCR assayb Leishmania DNA load
IC50 (lg/mL) 0.02 0.02 0.02
(CI 95%) (0.01–0.03) (0.01–0.03) (0.01–0.04)
IC90 (lg/mL) 0.04 0.04 0.04
(CI 95%) (0.01–0.15) (0.001–0.98) (0.002–0.76)
a Mean of the results of three independent experiments, each in triplicate.
b Mean of the results of two independent experiments, each in triplicate.
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L. infantum genomic DNA, and the result obtained (0.036 pg) corre-
sponds to less than a single parasite cell.
The potential to evaluate known antileishmanial substances
was tested using amphotericin B in an L. infantum amastigote-mac-
rophage model. The results of two experiments showed a dose-
dependent effect on parasite load, with an IC50 value of 0.02 lg/
mL and an IC90 value of 0.04 lg/mL. The same parasite load kinetics
were observed after the assessment of three independent experi-
ments with the classical method of microscopic counting using
Giemsa stained coverslips (Fig. 1), and exactly the same IC50 and
IC90 values were observed (Table 1). These data revealed the accu-
racy and sensitivity of the Leishmania qPCR assay when performed
with fewer replicates. Additionally, the protocol developed was
thoroughly tested, with special attention given to the removal of
the macrophages from the coverslips, the total DNA extraction
method applied and the analysis of the parasite load after qPCR
evaluation. All of these efforts culminated in a highly accurate
assessment of parasite load by Leishmania DNA content, as seen
in Fig. 1B. The mouse qPCR assay with the reference gene ACTB
was used to normalize data as well as to internally control for error
in qPCR assays (Huggett et al., 2005).
The advantages and disadvantages in using DNA and RNA
detection of the parasite in qPCR assays have been especially ad-
dressed when the objective is the monitoring of treatment in
which the detection of viable parasites is crucial. For Reimão
et al. (2011), DNA evaluation would not guarantee detection of liv-
ing parasites, since available drugs are known to act progressively
over a long period of time, resulting in a mixed population of living
and dead organisms. Additionally, the proper chemical stability of
the DNA molecule could hamper its degradation. Prina et al. (2007)
using an in vitro model with mouse macrophages and L-leucine es-
ter as a molecule that rapidly kills intracellular L. amazonensisamastigotes proved that kinetoplast and nuclear parasite DNA deg-
radation occur very rapidly after amastigote death. Their conclu-
sion was that qPCR assay with DNA evaluation assessed the
presence of viable parasites, and it represents a robust method
for diagnosis, and also for monitoring parasite reduction rate in
either animal models or drug-treated patients. Although it was
out of the scope of the present study to assess parasite viability,
our choice to work with DNA was also inﬂuenced by clinical expe-
rience and technical feasibility. Previous clinical studies of our
group using conventional PCR (Disch et al., 2004) and, more re-
cently, parasite kinetics studies with qPCR (unpublished observa-
tion) showed a rapid clearance of circulating Leishmania DNA in
peripheral blood after treatment of patients with visceral leish-
maniasis. Sudarshan et al. (2011) highlighted that qPCR assay using
kinetoplast DNA-speciﬁc primers was an important tool to esti-
mate parasite kinetics in the blood of patients during treatment,
and the test was used to detect cure and early relapses. Moreover,
when working with RNA, a ribonuclease-free environment must be
created, and one more step (cDNA synthesis) must be added to the
assay, making it less practical for the medium-scale drug screening
purpose.
In conclusion, qPCR proved to be an accurate method to assess
parasite load in an amastigote-macrophage model. In contrast to
the traditional method of expressing parasite number per macro-
phages, qPCR can be performed in a standardized medium-to-high
throughput procedure with no subjective evaluation.
Acknowledgments
Financial support for this study was provided by Fundação de
Amparo à Pesquisa do estado de Minas Gerais (FAPEMIG), Conselho
Nacional de Desenvolvimento Cientíﬁco e Tecnológico (CNPq) from
Brazil and Drugs for Neglected Diseases Initiative (DNDi).
L.I. Gomes et al. / Experimental Parasitology 131 (2012) 175–179 179References
Bretagne, S., Durand, R., Olivi, M., Garin, J.F., Sulahian, A., Rivollet, D., Vidaud, M.,
Deniau, M., 2001. Real-time PCR as a new tool for quantifying Leishmania
infantum in liver in infected mice. Clinical and Diagnostic Laboratory
Immunology 8, 828–831.
Chawla, B., Madhubala, R., 2010. Drug targets in Leishmania. Journal of Parasitic
Diseases 34, 1–13.
Croft, S.L., Seifert, K., Yardley, V., 2006. Current scenario of drug development for
leishmaniasis. Indian Journal of Medical Research 123, 399–410.
de Oliveira-Silva, F., de Morais-Teixeira, E., Rabello, A., 2008. Antileishmanial
activity of azithromycin against Leishmania (Leishmania) amazonensis,
Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi. The
American Journal of Tropical Medicine and Hygiene 78, 745–749.
Disch, J., Oliveira, M.C., Orsini, M., Rabello, A., 2004. Rapid clearance of circulating
Leishmania kinetoplast DNA after treatment of visceral leishmaniasis. Acta
Tropica 92, 279–283.
Dujardin, J.C., González-Pacanowska, D., Croft, S.L., Olesen, O.F., Späth, G.F., 2010.
Collaborative actions in anti-trypanosomatid chemotherapy with partners from
disease endemic areas. Trends in Parasitology 26, 395–403.
Fumarola, L., Spinelli, R., Brandonisio, O., 2004. In vitro assays for evaluation of drug
activity against Leishmania spp. Research in Microbiology 155, 224–230.
Garnier, T., Mäntylä, A., Järvinen, T., Lawrence, J., Brown, M., Croft, S., 2007. In vivo
studies on the antileishmanial activity of buparvaquone and its prodrugs.
Journal of Antimicrobial Chemotherapy 60, 802–810.
Giulietti, A., Overbergh, L., Valckx, D., Decallonne, B., Bouillon, R., Mathieu, C., 2001.
An overview of real-time quantitative PCR: applications to quantify cytokine
gene expression. Methods 25, 386–401.
Gupta, S., Nishi, 2011. Visceral leishmaniasis: experimental models for drug
discovery. Indian Journal of Medical Research 133, 27–39.
Huggett, J., Dheda, K., Bustin, S., Zumla, A., 2005. Real-time RT-PCR normalisation;
strategies and considerations. Genes and Immunity 6, 279–284.
Nicolas, L., Prina, E., Lang, T., Milon, G., 2002. Real-time PCR for detection and
quantitation of Leishmania in mouse tissues. Journal of Clinical Microbiology 40,
1666–1669.Ordóñez-Gutiérrez, L., Martínez, M., Rubio-Somoza, I., Díaz, I., Mendez, S., Alunda,
J.M., 2009. Leishmania infantum: antiproliferative effect of recombinant plant
cystatins on promastigotes and intracellular amastigotes estimated by direct
counting and real-time PCR. Experimental Parasitology 123, 341–346.
Overbergh, L., Valckx, D., Waer, M., Mathieu, C., 1999. Quantiﬁcation of murine
cytokine mRNAs using real time quantitative reverse transcriptase PCR.
Cytokine 11, 305–312.
Prina, E., Roux, E., Mattei, D., Milon, G., 2007. Leishmania DNA is rapidly degraded
following parasite death: an analysis by microscopy and real-time PCR.
Microbes and Infection 9, 1307–1315.
Reimão, J.Q., Colombo, F.A., Pereira-Chioccola, V.L., Tempone, A.G., 2011. In vitro and
experimental therapeutic studies of the calcium channel blocker bepridil:
detection of viable Leishmania (L.) chagasi by real-time PCR. Experimental
Parasitology 128, 111–115.
Rolão, N., Cortes, S., Rodrigues, O.R., Campino, L., 2004. Quantiﬁcation of Leishmania
infantum parasites in tissue biopsies by real-time polymerase chain reaction
and polymerase chain reaction-enzyme-linked immunosorbent assay. The
Journal of Parasitology 90, 1150–1154.
Seifert, K., 2011. Structures, targets and recent approaches in anti-leishmanial drug
discovery and development. The Open Medicinal Chemistry Journal 5, 31–39.
Sereno, D., Cordeiro da Silva, A., Mathieu-Daude, F., Ouaissi, A., 2007. Advances and
perspectives in Leishmania cell based drug-screening procedures. Parasitology
International 56, 3–7.
Sudarshan, M., Weirather, J.L., Wilson, M.E., Sundar, S., 2011. Study of parasite
kinetics with antileishmanial drugs using real-time quantitative PCR in Indian
visceral leishmaniasis. Journal of Antimicrobial Chemotherapy 66, 1751–1755.
van Eys, G.J., Schoone, G.J., Kroon, N.C., Ebeling, S.B., 1992. Sequence analysis of
small subunit ribosomal RNA genes and its use for detection and identiﬁcation
of Leishmania parasites. Molecular and Biochemical Parasitology 51, 133–142.
World Health Organization, 2011. Technical Report Series on the control of the
leishmaniases. < http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf>.
Wortmann, G., Sweeney, C., Houng, H.S., Aronson, N., Stiteler, J., Jackson, J.,
Ockenhouse, C., 2001. Rapid diagnosis of leishmaniasis by ﬂuorogenic
polymerase chain reaction. The American Journal of Tropical Medicine and
Hygiene 65, 583–587.
